Chronicle Journal: Finance

United Health Products Files IDE Pre-Submission with the FDA for Approval to Begin Human Trials of HemoStyp®

HENDERSON, Nev., June 19, 2018 (GLOBE NEWSWIRE) -- United Health Products, Inc. (UHP) (OTC:UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that after successfully completing a series of animal tests, it has filed an IDE pre-submission application with the Food and Drug Administration (FDA) to begin human trials of HemoStyp. The filing was made in conjunction with a previously filed Class III PMA submission application for HemoStyp for general surgical use in abdominal, cardiovascular and thoracic procedures to control bleeding sites.

An Investigational Device Exemption (IDE) allows an investigational device (i.e., a device that is the subject of a clinical study) to be used in order to collect safety and effectiveness data required to support a premarket approval (PMA). All statistical power calculations have been completed, and procedural protocols have been vetted for this submission. UHP expects to confer imminently with the FDA to confirm receipt of the Protocol, and to begin testing upon approval.

About IDE pre-submission:

About Premarket Approval (PMA):

About United Health Products
United Health Products develops, manufactures, and markets patented hemostatic gauze for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UHP is focused on identifying new markets and applications for its products, and expanding its current markets. For more on United Health Products visit:

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact: 877-358-3444/ IR Contact: Philippe Niemetz, PAN Consultants Ltd. 212-344-6464

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.